Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ASTRO BCC/cSCC guideline: definitive BED10 70-93.5 conventional, adjuvant nodal RT 6000-6600 cGy, no concurrent carboplatin with adjuvant RT for resected cSCC.
Four guidance documents, no new trial data. Skin carried the day with ASTRO's graded BCC/cSCC RT recommendations and GEC-ESTRO ACROP's depth-based brachy split (contact <5 mm, interstitial ≥5 mm). IMWG places RT for myeloma soft-tissue mass, not VCF stabilisation; COVID-era lung guidance lists 30Gy to 34Gy single-fraction SABR and 50Gy/5. Most rest on low-to-moderate or retrospective evidence.
read the full digest →Studies · 268
- IMWG consensus: cement augmentation for myeloma VCFs4-8 wk window: IMWG advises offering BKP or PV for painful myeloma VCFs, with VAS ≥6 triaging to immediate augmentation and up to 3 levels per session.
- GEC-ESTRO ACROP skin brachytherapy recommendationsDepth sets the technique: contact BT for skin tumours <5 mm deep, interstitial for ≥5 mm or curved surfaces; no standard dose schedule endorsed.
- ASTRO guideline: definitive and postoperative RT for BCC and cSCCThe guideline gives explicit strength and evidence grades for definitive RT, PORT, nodal RT, BED10 dose ranges and concurrent systemic therapy in non-metastatic BCC and cSCC. Most rest on low-to-mode…
- Reduced fractionation in lung RT during COVID-19COVID-era consensus on shorter curative lung RT: 30Gy to 34Gy single-fraction SABR, 50Gy in 5 fractions, and 15-fraction schedules modelled against 55Gy/20.
- NTCP, TCP and the TECs (QUANTEC, HyTEC, PENTEC)Narrative review of TCP/NTCP outcome modeling through the QUANTEC, HyTEC and PENTEC normal-tissue projects; no effect sizes reported in source.
- Biological principles of SBRT/SRS: indirect cell deathAbove ~10 Gy/fraction, SBRT/SRS adds indirect tumor cell death via vascular injury and antitumor immunity on top of direct cell kill.
- PENTEC vs QUANTEC/HyTEC: late effects in children vs adultsNo effect size reported in source; organ-by-organ synthesis finds pediatric late-effect risk similar, greater, or less than adult, depending on tissue and age.
- HyTEC carotid blowout and bleeding events in H&N SBRT reirradiationPooled 5-fx Dmax model TD50 45.7 Gy for major vessel bleeding after H&N SBRT reRT; carotid Dmax <20 to 30 Gy appears low risk.
- Trigeminal nerve contouring guidelines in H&N cancersUnresected macroscopic PNI: CTV-P1 = enhancing nerve + 5 mm; CTV-P2 extends ≥30 mm along nerve, skull base often recommended, brainstem if intracranial.
- CTV-P delineation consensus, laryngeal/hypopharyngeal/oropharyngeal/oral cavity SCCGTV-P+5 mm → CTV-P1 (high dose), GTV-P+10 mm → CTV-P2 (lower dose), both anatomically edited; hypopharynx may take 15 mm cranio-caudal.
- Neck node level delineation: 2013 update consensusConsensus CT boundaries for neck levels I-X, adding retropharyngeal, retro-styloid, parotid, bucco-facial and occipital groups; level selection and dose out of scope.
- Target volume selection and delineation (T and N), oral cavity/oropharynx/hypopharynx/larynx SCCConsensus nodal levels keyed to N category, plus 5 and 10 mm GTV expansions edited to anatomy, for primary RT of oral cavity and pharyngo-laryngeal SCC.